Form D · Pharmaceuticals
Jaguar Health, Inc.
San Francisco, CA · CIK 0001585608
Offering snapshot reported Jul 1, 2026 · SEC filing
- Reported sold
- $2M Offering amount: $2M
- Investors reported
- 2 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Jun 9, 2026 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Jul 1, 2026 | Initial | $2,000,000 | No comparison | 2 | SEC filing |
| Jul 1, 2026 | Initial | $40,800,000 | No comparison | 1 | SEC filing |
| Nov 24, 2025 | Initial | $10,810,000 | No comparison | 0 | SEC filing |
| Oct 10, 2025 | Initial | $1,000,000 | No comparison | 1 | SEC filing |
| Sep 23, 2025 | Initial | $2,377,000 | No comparison | 15 | SEC filing |
| May 28, 2025 | Initial | $1,500,003 | No comparison | 3 | SEC filing |
| Nov 30, 2023 | Initial | $60,000 | No comparison | 1 | SEC filing |
| May 11, 2023 | Initial | $1,832,304 | No comparison | 3 | SEC filing |
| May 11, 2023 | Initial | $1,857,453 | No comparison | 6 | SEC filing |
| Sep 23, 2022 | Initial | $7,140 | No comparison | 1 | SEC filing |
| Sep 2, 2022 | Initial | $12,000,000 | No comparison | 1 | SEC filing |
| Jul 8, 2022 | Initial | $300,000 | No comparison | 1 | SEC filing |
| Apr 26, 2022 | Initial | $50,820 | No comparison | 1 | SEC filing |
| Apr 25, 2022 | Initial | $7,572 | No comparison | 1 | SEC filing |
| Apr 25, 2022 | Initial | $39,800 | No comparison | 1 | SEC filing |
| Sep 24, 2021 | Initial | $776,197 | No comparison | 4 | SEC filing |
| Mar 26, 2021 | Initial | $10,000,000 | No comparison | 1 | SEC filing |
| Feb 4, 2021 | Initial | $12,000,000 | No comparison | 1 | SEC filing |
| Feb 4, 2021 | Initial | $6,220,812 | No comparison | 1 | SEC filing |
| Sep 17, 2020 | Initial | $1,087,500 | No comparison | 1 | SEC filing |
| Jun 5, 2020 | Initial | $4,447,779 | No comparison | 11 | SEC filing |
| Apr 8, 2020 | Initial | $720,000 | No comparison | 6 | SEC filing |
| Apr 7, 2020 | Initial | $2,030,000 | No comparison | 1 | SEC filing |
| Jan 6, 2020 | Initial | $1,500,000 | No comparison | 8 | SEC filing |
| Apr 3, 2019 | Initial | $800,000 | No comparison | 2 | SEC filing |
| Sep 27, 2018 | Initial | $774,844 | No comparison | 2 | SEC filing |
| Sep 24, 2018 | Initial | $569,998 | No comparison | 1 | SEC filing |
| Apr 2, 2018 | Initial | $9,199,001 | No comparison | 1 | SEC filing |
| Apr 2, 2018 | Initial | $1,090,340 | No comparison | 1 | SEC filing |
| Apr 2, 2018 | Initial | $2,240,909 | No comparison | 1 | SEC filing |
| Apr 2, 2018 | Initial | $4,999,999 | No comparison | 4 | SEC filing |
| Mar 30, 2018 | Initial | $1,587,500 | No comparison | 11 | SEC filing |
| Mar 30, 2018 | Initial | $2,155,000 | No comparison | 1 | SEC filing |
| Jan 11, 2018 | Initial | $801,100 | No comparison | 6 | SEC filing |
| Aug 30, 2017 | Initial | $44,796,553 | No comparison | 10 | SEC filing |
| Apr 2, 2015 | Initial | $1,000,000 | No comparison | 1 | SEC filing |
| Mar 9, 2015 | Initial | $900,000 | No comparison | 5 | SEC filing |
| Mar 6, 2015 | Initial | $1,000,000 | No comparison | 2 | SEC filing |
| Sep 12, 2014 | Initial | $1,112,500 | No comparison | 1 | SEC filing |
| Jun 16, 2014 | Initial | $300,000 | No comparison | 2 | SEC filing |
| Jun 4, 2014 | Amendment | $525,000 | $325,000vs Sep 5, 2013 | 4 | SEC filing |
| May 7, 2014 | Amendment | $6,777,338 | $4,777,338vs Feb 10, 2014 | 9 | SEC filing |
| Feb 10, 2014 | Initial | $2,000,000 | No comparison | 1 | SEC filing |
| Sep 5, 2013 | Initial | $200,000 | No comparison | 2 | SEC filing |
Offering details
- Securities
- Equity
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-589226
Source: Form D, filed Jul 1, 2026. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No matching detailed fund disclosure was found in the latest imported ADV filings. This does not establish that the issuer has no adviser.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Ari Azhir | Director |
| James Bochnowski | Director |
| Joseph Bochnowski | Director |
| Pravin Chaturvedi | Executive |
| Lisa Conte | Director, Executive |
| Greg Divas | Director |
| Greg J. Divis | Director |
| Anula Jayasuriya | Director |
| Jeffrey C. Johnson | Director |
| Jeffery Johnson | Director |
| John Kallassy | Executive |
| Folkert Kamphuis | Director |
| Steven King | Executive |
| Carol Lizak | Executive |
| Carol L Izak | Executive |
| Murray Mac Naughtan | Director |
| Serge Martinod | Executive |
| John Micek Iii | Director |
| John Micek, Iii | Director |
| Jiahao Qui | Director |
| Joe Qui | Director |
| Jonathan Siegel | Director |
| Charles Thompson | Executive |
| Charles Thomspn | Executive |
| Jonathan Wolin | Executive |
| Jonathan Woling | Executive |
| Karen S. Wright | Executive |
| Zhi Yang | Director |
Issuer details
Industry: Pharmaceuticals (See others in industry)
Address:
200 Pine St., Ste 400
San Francisco, CA, 94104
Phone: 415-371-8300
San Francisco, CA, 94104
Phone: 415-371-8300